Natera, Inc. (NASDAQ:NTRA) Shares Bought by Atika Capital Management LLC

Atika Capital Management LLC lifted its stake in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 12.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 71,700 shares of the medical research company's stock after acquiring an additional 7,700 shares during the quarter. Natera makes up approximately 1.2% of Atika Capital Management LLC's holdings, making the stock its 22nd biggest position. Atika Capital Management LLC owned about 0.05% of Natera worth $11,350,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Wilmington Savings Fund Society FSB purchased a new position in shares of Natera during the third quarter valued at about $385,000. Everence Capital Management Inc. purchased a new stake in Natera in the 4th quarter worth about $573,000. Smartleaf Asset Management LLC lifted its stake in shares of Natera by 50.3% during the 4th quarter. Smartleaf Asset Management LLC now owns 657 shares of the medical research company's stock worth $104,000 after acquiring an additional 220 shares during the last quarter. SeaBridge Investment Advisors LLC bought a new stake in shares of Natera during the fourth quarter worth $2,894,000. Finally, SYM FINANCIAL Corp purchased a new stake in Natera in the 4th quarter valued at about $256,000. 99.90% of the stock is owned by hedge funds and other institutional investors.

Natera Stock Performance

NASDAQ NTRA traded up $1.64 on Friday, hitting $144.92. 409,923 shares of the company's stock traded hands, compared to its average volume of 1,744,943. The firm's 50-day moving average price is $153.18 and its two-hundred day moving average price is $151.89. The firm has a market capitalization of $19.59 billion, a PE ratio of -82.34 and a beta of 1.80. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33. Natera, Inc. has a 1-year low of $83.13 and a 1-year high of $183.00.

Remove Ads

Natera (NASDAQ:NTRA - Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The medical research company reported ($0.41) EPS for the quarter, beating the consensus estimate of ($0.42) by $0.01. The company had revenue of $476.10 million for the quarter, compared to analyst estimates of $447.91 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. As a group, analysts expect that Natera, Inc. will post -1.49 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on NTRA. The Goldman Sachs Group increased their price objective on shares of Natera from $160.00 to $190.00 and gave the company a "buy" rating in a research note on Tuesday, January 28th. Canaccord Genuity Group reaffirmed a "buy" rating and set a $180.00 price objective on shares of Natera in a research report on Wednesday, February 26th. JPMorgan Chase & Co. lifted their target price on Natera from $160.00 to $200.00 and gave the company an "overweight" rating in a research note on Friday, December 13th. Morgan Stanley raised their price target on shares of Natera from $176.00 to $185.00 and gave the company an "overweight" rating in a report on Wednesday, March 5th. Finally, Piper Sandler increased their target price on shares of Natera from $200.00 to $205.00 and gave the company an "overweight" rating in a research report on Tuesday, March 4th. One analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $175.76.

Insider Buying and Selling at Natera

In other news, CFO Michael Burkes Brophy sold 25,931 shares of the stock in a transaction dated Wednesday, January 22nd. The shares were sold at an average price of $164.97, for a total transaction of $4,277,837.07. Following the sale, the chief financial officer now directly owns 109,665 shares of the company's stock, valued at $18,091,435.05. This represents a 19.12 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Gail Boxer Marcus sold 4,000 shares of the company's stock in a transaction dated Tuesday, April 1st. The stock was sold at an average price of $140.78, for a total value of $563,120.00. Following the completion of the transaction, the director now directly owns 9,704 shares of the company's stock, valued at $1,366,129.12. The trade was a 29.19 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 325,922 shares of company stock valued at $51,603,664. 7.60% of the stock is owned by company insiders.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.